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Background: Paroxonase (PON-1) is an HDL-associated enzyme with atheroprotective functions that are impaired in dysfunctional HDL. 
Diminished serum arylesterase activity, one of several functions of PON-1, is associated with heightened systemic oxidative stress and 
atherosclerosis risk. The prognostic and clinical utility of measuring arylesterase activity has not been established.
Methods: We measured serum arylesterase activity in 3,568 stable subjects who underwent elective coronary angiography, had no evidence of 
acute coronary syndrome (troponin negative), and prospectively followed major adverse cardiac events (MACE = death, myocardial infarction, stroke) 
over 3 years.
Results: In our study cohort (age 63±11, 66% male, 29% diabetes mellitus, 70% hypertension), low serum arylesterase activity was associated with 
increased risk for 3-year MACE (Q4 vs Q1, Hazard Ratio 2.62, 95%CI 1.98-3.48, p<0.01). This remained significant after adjusting for Framingham 
Risk Score, C-reactive protein, and creatinine clearance (HR 2.08, 95%CI 1.56-2.78, p<0.01). Addition of serum arylesterase activity to a model of 
Framingham Risk Score contributes to net reclassification improvement (NRI) of 13.6% (p<0.0001).
Conclusion: Identifying diminished serum arylesterase activity can provide incremental prognostic value and 
clinical reclassification of stable cardiac patients at higher risk of developing major adverse cardiac events.
